BI 836826 + gemcitabine + oxaliplatin

A combination therapy consisting of **BI 836826**, a chimeric mouse–human monoclonal antibody that targets human CD37, with **gemcitabine** and **oxaliplatin** (collectively known as GemOx). BI 836826 binds to CD37, a transmembrane protein highly expressed on mature B lymphocytes, leading to antibody-dependent cell-mediated cytotoxicity and direct proapoptotic activity. **Gemcitabine** is a nucleoside analog, and **oxaliplatin** is a platinum-based chemotherapy; both act as cytotoxic agents by interfering with DNA replication or function. This combination has been clinically evaluated in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma. The regimen is delivered by intravenous infusion and was studied in a phase I dose-escalation setting to determine safety, tolerability, and preliminary efficacy. The most frequent adverse events were hematologic toxicities, such as neutropenia, thrombocytopenia, and anemia.

Other names

GemOx + BI 836826